Science
Moderna and Merck's Personalized mRNA Cancer Vaccine Succeeds in Phase 3, Marking a Watershed for Precision Oncology
The INTerpath-001 trial showed intismeran autogene plus Keytruda significantly improved recurrence-free survival in high-risk melanoma patients. It's the first late-stage win for individualized mRNA cancer therapy.
Science Desk